Hutch News

Hutch News

Stories tagged 'Matthias Stephan'

Dr. Matthias Stephan named Allen Distinguished Investigator

The $1.5 million award will help translate cutting-edge nanoparticle immunotherapy approach to the clinic

Oct. 30, 2018 | By Sabrina Richards / Fred Hutch News Service

Fred Hutch immunobioengineer Dr. Matthias Stephan, who is developing the use of immune-cell-programming nanoparticles as a cancer treatment, has been named a 2018 Allen Distinguished Investigator by The Paul G. Allen Frontiers Group.

View story >


Improving cancer vaccines with T-cell programming nanoparticles

Dr. Matthias Stephan receives grant to develop cancer vaccine–optimizing, TCR-programming nanotechnology

July 31, 2018 | By Sabrina Richards / Fred Hutch News Service

Fred Hutch immunobioengineer Dr. Matthias Stephan has received an award to support the development of a combined T-cell programming, cancer-vaccine strategy to treat cancer.

View story >


Nanoparticles open doors to cancer-fighting CAR T cells

Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy

July 2, 2018 | By Sabrina Richards / Fred Hutch News Service

Scientists at Fred Hutchinson Cancer Research Center have developed a cheap way to make cancers temporarily vulnerable to immune attack using liposome-based nanoparticles to carry immune-boosting drugs deep into tumors.

View story >


Nanoparticles take immunotherapy in new direction

Hutch scientist to use nanoparticles to reprogram macrophages to tackle brain tumors

May 30, 2018 | By Sabrina Richards / Fred Hutch News Service

Dr. Fan Zhang has received funding from the American Brain Tumor Association to develop nanoparticles that can tackle a type of brain cancer called glioblastoma.

View story >


10 highlights of Fred Hutch science in 2017

A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

Dec. 28, 2017 | by Sabin Russell and Susan Keown / Fred Hutch News Service

It's been a year of breakthroughs at Fred Hutch. Here are 10 of our favorites.

View story >


New nanoparticles make targeted, temporary gene therapy possible

‘Hit-and-run’ technology could improve immunotherapy and HIV cure research

Aug. 30, 2017 | By Sabrina Richards / Fred Hutch News Service

'Hit-and-run' technology could improve immunotherapy and HIV cure research

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.